Johnson & Johnson (JNJ) remains one of the most resilient and innovative names in the healthcare industry, not just for its robust portfolio of healthcare products but also for its relentless commitment to returning value to shareholders. As of 2025, JNJ continues to carry the status of a "Dividend King," a title bestowed on companies that have consistently increased their dividend payouts for 50 consecutive years or more. Valued at $425.3 billion, JNJ stock has surged 22% year-to-date (YTD), compared to ...